Cargando…
Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubul...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572507/ https://www.ncbi.nlm.nih.gov/pubmed/31117208 http://dx.doi.org/10.3390/medicina55050176 |